Mineralocorticoid receptor antagonists for VEGF-pathway inhibitor-associated hypertension and proteinuria: biological rationale, clinical evidence, and a hypothesis-generating framework
Medical Oncology · 09.11.2026 · 43 (12)
DOI: 10.1007/s12032-026-03498-x ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medical Oncology, online erschienen am 09.11.2026. Verfasst von Tamotsu Sagawa und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, National Hospital Organization Hokkaido Cancer Center, 2-3-54 Kikusui 4-jo, Shiroishi-ku, Sapporo, Hokkaido, 003-0804…. Hauptthemen laut MEDLINE: Hypertension, Proteinuria, Mineralocorticoid Receptor Antagonists, Vascular Endothelial Growth Factor A. Die Arbeit nennt 58 Literaturangaben.
Abstract (Originalsprache)
In this narrative review, we integrate mechanistic, clinical, and cardiorenal evidence relevant to mineralocorticoid receptor antagonists (MRAs) in vascular endothelial growth factor (VEGF)-pathway inhibitor-associated hypertension and proteinuria. VEGF-pathway inhibition can cause systemic endothelial dysfunction, altered nitric oxide and endothelin signaling, and heterogeneous glomerular injury, including thrombotic microangiopathy (TMA) with VEGF-ligand blockade and podocytopathy with some VEGFR tyrosine kinase inhibitors. Renin-angiotensin-aldosterone system (RAAS) blockade, dihydropyridine calcium-channel blockers, careful blood pressure control, quantitative proteinuria assessment, and recognition of structural kidney injury remain the established management foundation. MR blockade is biologically attractive because it can lower blood pressure and proteinuria and modulate inflammatory, vascular, and glomerular pathways; however, most supporting evidence is extrapolated from resistant hypertension and chronic kidney disease. Direct oncology evidence is limited to small, nonrandomized datasets and remains hypothesis-generating. Accordingly, MRAs should not be positioned as a preferred third-line antihypertensive class or as established prophylaxis for VEGF-pathway inhibitor-associated renal toxicity. They may be considered as a phenotype-selected option when hypertension and non-nephrotic proteinuria coexist, conventional diuretic escalation is clinically unattractive, product-specific kidney function and potassium criteria are met, and close monitoring is feasible. Prospective oncology studies using kidney-function, structural, and treatment-continuity endpoints are required before routine adoption can be recommended.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, National Hospital Organization Hokkaido Cancer Center, 2-3-54 Kikusui 4-jo, Shiroishi-ku, Sapporo, Hokkaido, 003-0804, Japan. sagawa.tamotsu.dy@mail.hosp.go.jp.
- Department of Pharmacy, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan.
- Department of Nursing, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan.
- Department of Gastroenterology, National Hospital Organization Hokkaido Cancer Center, 2-3-54 Kikusui 4-jo, Shiroishi-ku, Sapporo, Hokkaido, 003-0804, Japan.
Zitieren
APA
Sagawa, T., Umehara, K., Izumi, M., Kawamura, K., & Fujikawa, K. (2026). Mineralocorticoid receptor antagonists for VEGF-pathway inhibitor-associated hypertension and proteinuria: biological rationale, clinical evidence, and a hypothesis-generating framework. Medical Oncology, 43(12). https://doi.org/10.1007/s12032-026-03498-x
Vancouver
Sagawa T, Umehara K, Izumi M, Kawamura K, Fujikawa K. Mineralocorticoid receptor antagonists for VEGF-pathway inhibitor-associated hypertension and proteinuria: biological rationale, clinical evidence, and a hypothesis-generating framework. Medical Oncology. 2026;43(12). doi:10.1007/s12032-026-03498-x
BibTeX
@article{Sagawa2026,
author = {Sagawa, Tamotsu and Umehara, Kengo and Izumi, Miho and Kawamura, Kentaro and Fujikawa, Koshi},
title = {Mineralocorticoid receptor antagonists for VEGF-pathway inhibitor-associated hypertension and proteinuria: biological rationale, clinical evidence, and a hypothesis-generating framework},
journal = {Medical Oncology},
year = {2026},
volume = {43},
number = {12},
doi = {10.1007/s12032-026-03498-x}
}
EUVIMED